

Anna R Hemnes

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3714963/anna-r-hemnes-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

113
papers

4,067
citations

34
h-index

62
g-index

125
ext. papers

5,147
ext. citations

5.1
avg, IF

5.36
L-index

#	Paper	IF	Citations
113	Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry.. <i>Journal of the American Heart Association</i> , 2022 , e024969	6	7
112	Introduction to Review Series on Pulmonary Vascular Disease and Right Ventricular Heart Failure.. <i>Circulation Research</i> , 2022 , 130, 1362-1364	15.7	0
111	Integrative Omics to Characterize and Classify Pulmonary Vascular Disease. <i>Clinics in Chest Medicine</i> , 2021 , 42, 195-205	5.3	1
110	NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease[Classification: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2040-2052	15.1	6
109	Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE. <i>Journal of Heart and Lung Transplantation</i> , 2021 , 40, 279-288	5.8	3
108	Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. <i>Circulation: Heart Failure</i> , 2021 , 14,	7.6	1
107	Metabolics of PH - an update. <i>Current Opinion in Pulmonary Medicine</i> , 2021 , 27, 329-334	3	
106	Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2). <i>Hepatology</i> , 2021 , 73, 726-737	11.2	9
105	Daily Step Counts Are Associated with Hospitalization Risk in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, 1338-1340	10.2	2
104	A Mobile Health Intervention to Increase Physical Activity in Pulmonary Arterial Hypertension. <i>Chest</i> , 2021 , 160, 1042-1052	5.3	4
103	Right Ventricular Pathobiology 2021 , 15-26		
102	Evidence of pulmonary arterial hypertension in two patients with common variable immunodeficiency. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894020922792	2.7	1
101	Sex hormone exposure and reproductive factors in pulmonary arterial hypertension: a case-control study. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894020908786	2.7	1
100	AuthorsReply: role of natriuretic peptide receptor C signalling in obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894020910979	2.7	0
99	A multifaceted investigation into molecular associations of chronic thromboembolic pulmonary hypertension pathogenesis. <i>JRSM Cardiovascular Disease</i> , 2020 , 9, 2048004020906994	1.1	0
98	Comprehensive Diagnostic Evaluation of Cardiovascular Physiology in Patients With Pulmonary Vascular Disease: Insights From the PVDOMICS Program. <i>Circulation: Heart Failure</i> , 2020 , 13, e006363	7.6	6
97	dysfunction impairs insulin signaling and glucose homeostasis in cardiomyocytes. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020 , 318, L429-L441	5.8	8

96	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. <i>Chest</i> , 2020 , 157, 955-965	5.3	14
95	Biomarker-specific differences between transpulmonary and peripheral arterial-venous blood sampling in patients with pulmonary hypertension. <i>Biomarkers</i> , 2020 , 25, 131-136	2.6	
94	Metabolic syndrome, neurohumoral modulation, and pulmonary arterial hypertension. <i>British Journal of Pharmacology</i> , 2020 , 177, 1457-1471	8.6	13
93	Expression of a Human Caveolin-1 Mutation in Mice Drives Inflammatory and Metabolic Defect-Associated Pulmonary Arterial Hypertension. <i>Frontiers in Medicine</i> , 2020 , 7, 540	4.9	1
92	Influence of Body Weight and Diabetes Mellitus in Patients With Pulmonary Hypertension. <i>American Journal of Cardiology</i> , 2020 , 134, 130-137	3	4
91	Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894020957234	2.7	3
90	Treatment of right ventricular dysfunction and heart failure in pulmonary arterial hypertension. <i>Cardiovascular Diagnosis and Therapy</i> , 2020 , 10, 1659-1674	2.6	6
89	Molecular mechanisms of right ventricular dysfunction in pulmonary arterial hypertension: focus on the coronary vasculature, sex hormones, and glucose/lipid metabolism. <i>Cardiovascular Diagnosis and Therapy</i> , 2020 , 10, 1522-1540	2.6	5
88	Mechanistic Phase II Clinical Trial of Metformin in Pulmonary Arterial Hypertension. <i>Journal of the American Heart Association</i> , 2020 , 9, e018349	6	13
87	Novel Documentation of Onset and Rapid Advancement of Pulmonary Arterial Hypertension without Symptoms in BMPR2 Mutation Carriers: Cautionary Tales?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 1587-1589	10.2	0
86	Six-minute walk distance in healthy young adults. <i>Respiratory Medicine</i> , 2020 , 165, 105933	4.6	14
85	Obesity in Pulmonary Arterial Hypertension (PAH): The Pulmonary Hypertension Association Registry (PHAR). <i>Annals of the American Thoracic Society</i> , 2020 ,	4.7	3
84	Association of Mild Echocardiographic Pulmonary Hypertension With Mortality and Right Ventricular Function. <i>JAMA Cardiology</i> , 2019 , 4, 1112-1121	16.2	31
83	High rates of medication adherence in patients with pulmonary arterial hypertension: An integrated specialty pharmacy approach. <i>PLoS ONE</i> , 2019 , 14, e0217798	3.7	13
82	Human PAH is characterized by a pattern of lipid-related insulin resistance. <i>JCI Insight</i> , 2019 , 4,	9.9	36
81	Approach to a patient with pulmonary hypertension. <i>Journal of Geriatric Cardiology</i> , 2019 , 16, 478-481	1.7	1
80	Natriuretic peptide receptor C contributes to disproportionate right ventricular hypertrophy in a rodent model of obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension. <i>Pulmonary Circulation</i> , 2019 , 9, 2045894019878599	2.7	11
79	Reduced free-living activity levels in pulmonary arterial hypertension patients. <i>Pulmonary Circulation</i> , 2019 , 9, 2045894018814182	2.7	5

78	Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	148
77	Adverse physiologic effects of Western diet on right ventricular structure and function: role of lipid accumulation and metabolic therapy. <i>Pulmonary Circulation</i> , 2019 , 9, 2045894018817741	2.7	11
76	Diabetes Mellitus Associates with Increased Right Ventricular Afterload and Remodeling in Pulmonary Arterial Hypertension. <i>American Journal of Medicine</i> , 2018 , 131, 702.e7-702.e13	2.4	14
75	Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 166-174	10.2	14
74	The transpulmonary ratio of endothelin 1 is elevated in patients with preserved left ventricular ejection fraction and combined pre- and post-capillary pulmonary hypertension. <i>Pulmonary Circulation</i> , 2018 , 8, 2045893217745019	2.7	20
73	Using Omics to Understand and Treat Pulmonary Vascular Disease. <i>Frontiers in Medicine</i> , 2018 , 5, 157	4.9	8
72	Female Sex and Gender in Lung/Sleep Health and Disease. Increased Understanding of Basic Biological, Pathophysiological, and Behavioral Mechanisms Leading to Better Health for Female Patients with Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 850-858	10.2	44
71	Racial differences in patients referred for right heart catheterization and risk of pulmonary hypertension. <i>Pulmonary Circulation</i> , 2018 , 8, 2045894018764273	2.7	9
70	Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, e15-e43	10.2	105
69	A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	132
68	Current and Emerging Biomarkers for Pulmonary Hypertension. <i>Advances in Pulmonary Hypertension</i> , 2018 , 16, 136-140	0.5	1
67	Features Associated With Discordance Between Pulmonary Arterial Wedge Pressure and Left Ventricular End Diastolic Pressure in Clinical Practice: Implications for Pulmonary Hypertension Classification. <i>Chest</i> , 2018 , 154, 1099-1107	5.3	21
66	Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2018 , 8, 2045894018800544	2.7	3
65	Lack of a Tricuspid Regurgitation Doppler Signal and Pulmonary Hypertension by Invasive Measurement. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	25
64	Update on chronic thromboembolic pulmonary hypertension. <i>Trends in Cardiovascular Medicine</i> , 2017 , 27, 29-37	6.9	28
63	Translational Advances in the Field of Pulmonary Hypertension Molecular Medicine of Pulmonary Arterial Hypertension. From Population Genetics to Precision Medicine and Gene Editing. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 23-31	10.2	27
62	Identifying "super responders" in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2017 , 7, 300-311	7	7
61	Echocardiographic Pulmonary Artery Systolic Pressure in the Coronary Artery Risk Development in Young Adults (CARDIA) Study: Associations With Race and Metabolic Dysregulation. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	16

60	End-Tidal Carbon Dioxide as a Prognostic Feature in Pulmonary Arterial Hypertension. <i>Annals of the American Thoracic Society</i> , 2017 , 14, 896-902	4.7	3
59	Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension. <i>JAMA Cardiology</i> , 2017 , 2, 1361-1368	16.2	72
58	Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	41
57	Pulmonary vascular effect of insulin in a rodent model of pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2017 , 7, 624-634	2.7	15
56	Dysfunctional BMPR2 signaling drives an abnormal endothelial requirement for glutamine in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2017 , 7, 186-199	2.7	38
55	Reply: Tidal Carbon Dioxide as a Prognostic Feature in Inoperable Chronic Thromboembolic Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , 2017 , 14, 1604-1605	4.7	
54	Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled. <i>European Respiratory Review</i> , 2017 , 26,	9.8	47
53	PVDOMICS: A Multi-Center Study to Improve Understanding of Pulmonary Vascular Disease Through Phenomics. <i>Circulation Research</i> , 2017 , 121, 1136-1139	15.7	58
52	Disruption of lineage specification in adult pulmonary mesenchymal progenitor cells promotes microvascular dysfunction. <i>Journal of Clinical Investigation</i> , 2017 , 127, 2262-2276	15.9	29
51	Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension. <i>Pulmonary Circulation</i> , 2016 , 6, 145-54	2.7	39
50	Antagonism of the thromboxane-prostanoid receptor is cardioprotective against right ventricular pressure overload. <i>Pulmonary Circulation</i> , 2016 , 6, 211-23	2.7	12
49	Shared gene expression patterns in mesenchymal progenitors derived from lung and epidermis in pulmonary arterial hypertension: identifying key pathways in pulmonary vascular disease. <i>Pulmonary Circulation</i> , 2016 , 6, 483-497	2.7	16
48	Severity of pulmonary hypertension and obesity are not associated with worse functional outcomes after pulmonary thromboendarterectomy. <i>Pulmonary Circulation</i> , 2016 , 6, 174-80	2.7	2
47	Women's Health and Lung Development and Disease. <i>Obstetrics and Gynecology Clinics of North America</i> , 2016 , 43, 307-23	3.3	5
46	Valsalva Maneuver in Pulmonary Arterial Hypertension: Susceptibility to Syncope and Autonomic Dysfunction. <i>Chest</i> , 2016 , 149, 1252-60	5.3	12
45	Fatty Acid Metabolic Defects and Right Ventricular Lipotoxicity in Human Pulmonary Arterial Hypertension. <i>Circulation</i> , 2016 , 133, 1936-44	16.7	114
44	Endothelial HIF signaling regulates pulmonary fibrosis-associated pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2016 , 310, L249-62	5.8	47
43	Estrogen Metabolite 16 β -Hydroxyestrone Exacerbates Bone Morphogenetic Protein Receptor Type II-Associated Pulmonary Arterial Hypertension Through MicroRNA-29-Mediated Modulation of Cellular Metabolism. <i>Circulation</i> , 2016 , 133, 82-97	16.7	66

42	Clinical and Biological Insights Into Combined Post- and Pre-Capillary Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2525-2536	15.1	111
41	Parenteral Prostanoid Use at a Tertiary Referral Center: A Retrospective Cohort Study. <i>Chest</i> , 2016 , 149, 660-6	5.3	7
40	Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 194, 719-28	10.2	57
39	Hemodynamic evidence of vascular remodeling in combined post- and precapillary pulmonary hypertension. <i>Pulmonary Circulation</i> , 2016 , 6, 313-21	2.7	33
38	Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers. <i>Pulmonary Circulation</i> , 2015 , 5, 356-63	2.7	32
37	Fatty acid metabolism in pulmonary arterial hypertension: role in right ventricular dysfunction and hypertrophy. <i>Pulmonary Circulation</i> , 2015 , 5, 269-78	2.7	51
36	Prognostic value of acute vasodilator response in pulmonary arterial hypertension: beyond the "classic" responders. <i>Journal of Heart and Lung Transplantation</i> , 2015 , 34, 312-8	5.8	11
35	Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute. <i>Pulmonary Circulation</i> , 2015 , 5, 435-65	2.7	154
34	Expression of mutant bone morphogenetic protein receptor II worsens pulmonary hypertension secondary to pulmonary fibrosis. <i>Pulmonary Circulation</i> , 2015 , 5, 681-90	2.7	24
33	Effect of acute arteriolar vasodilation on capacitance and resistance in pulmonary arterial hypertension. <i>Chest</i> , 2015 , 147, 1080-1085	5.3	17
32	Right ventricular protein expression profile in end-stage heart failure. <i>Pulmonary Circulation</i> , 2015 , 5, 481-97	2.7	11
31	Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension. <i>Circulation</i> , 2015 , 131, 401-9; discussion 409	16.7	60
30	EIF2AK4 mutations in pulmonary capillary hemangiomatosis. <i>Chest</i> , 2014 , 145, 231-236	5.3	143
29	Elevation of plasma cell-free hemoglobin in pulmonary arterial hypertension. <i>Chest</i> , 2014 , 146, 1478-1485	5.3	29
28	Causes of pulmonary hypertension in the elderly. <i>Chest</i> , 2014 , 146, 159-166	5.3	39
27	NF- κ B Activation Exacerbates, but Is not Required for Murine Bmpr2-Related Pulmonary Hypertension. <i>Diseases (Basel, Switzerland)</i> , 2014 , 2, 148-167	4.4	5
26	Identification of a common Wnt-associated genetic signature across multiple cell types in pulmonary arterial hypertension. <i>American Journal of Physiology - Cell Physiology</i> , 2014 , 307, C415-30	5.4	46
25	Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014 , 189, 325-34	10.2	106

24	Variability in hemodynamic evaluation of pulmonary hypertension at large referral centers. <i>Pulmonary Circulation</i> , 2014 , 4, 679-84	2.7	6
23	Impact of diabetes on survival and right ventricular compensation in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2014 , 4, 311-8	2.7	40
22	Prostanoids but not oral therapies improve right ventricular function in pulmonary arterial hypertension. <i>JACC: Heart Failure</i> , 2013 , 1, 300-307	7.9	23
21	Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming. <i>Pulmonary Circulation</i> , 2012 , 2, 201-13	2.7	95
20	Testosterone negatively regulates right ventricular load stress responses in mice. <i>Pulmonary Circulation</i> , 2012 , 2, 352-8	2.7	49
19	Physical activity limitation as measured by accelerometry in pulmonary arterial hypertension. <i>Chest</i> , 2012 , 142, 1391-1398	5.3	49
18	Chasing Pulmonary Hypertension: 1980-2012. <i>Advances in Pulmonary Hypertension</i> , 2012 , 11, 121-123	0.5	
17	Experimental and transgenic models of pulmonary hypertension. <i>Comprehensive Physiology</i> , 2011 , 1, 769-82	7.7	19
16	Unrecognized glucose intolerance is common in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2011 , 30, 904-11	5.8	105
15	End tidal CO(2) tension: pulmonary arterial hypertension vs pulmonary venous hypertension and response to treatment. <i>Chest</i> , 2011 , 140, 1267-1273	5.3	17
14	Phosphodiesterase-5A (PDE5A) is localized to the endothelial caveolae and modulates NOS3 activity. <i>Cardiovascular Research</i> , 2011 , 90, 353-63	9.9	27
13	Pulmonary Hypertension is Prevalent in Catheter and Arterio-Venous Access Hemodialysis. <i>Nephrology Research & Reviews</i> , 2010 , 2, 10-14		
12	The right ventricle in pulmonary hypertension: from dogma to data. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 182, 586-8	10.2	5
11	Association of the metabolic syndrome with pulmonary venous hypertension. <i>Chest</i> , 2009 , 136, 31-36	5.3	137
10	Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation. <i>Liver Transplantation</i> , 2009 , 15, 15-9	4.5	82
9	Congenital pulmonary artery stenoses masquerading as chronic thromboembolic disease. <i>Journal of Heart and Lung Transplantation</i> , 2009 , 28, 1110-1	5.8	
8	Impact of medical residency on knowledge of asthma. <i>Journal of Asthma</i> , 2009 , 46, 36-40	1.9	4
7	PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2008 , 294, L24-33	5.8	112

6	Poor outcomes associated with drainage of pericardial effusions in patients with pulmonary arterial hypertension. <i>Southern Medical Journal</i> , 2008 , 101, 490-4	0.6	43
5	Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2006 , 4, 293-300	2.5	41
4	Tricuspid annular displacement predicts survival in pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 174, 1034-41	10.2	794
3	Diagnosis and Management of Secondary Pulmonary Hypertension. <i>Fundamental and Clinical Cardiology</i> , 2006 , 247-258		1
2	Diagnosing acute pancreatitis. <i>American Journal of Medicine</i> , 2005 , 118, 109-10	2.4	
1	A pressing situation. <i>American Journal of Medicine</i> , 2005 , 118, 1347-9	2.4	0